A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q). (Q53339839)
Jump to navigation
Jump to search
scientific article published on 26 February 2013
Language | Label | Description | Also known as |
---|---|---|---|
English | A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q). |
scientific article published on 26 February 2013 |
Statements
A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q) (English)
V Sardnal
A Rouquette
S Kaltenbach
C Bally
V Chesnais
C Leschi
L Ades
A Toma
26 February 2013
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference